Glenmark Pharmaceuticals soars on getting EIR with VAI status for USA manufacturing facility
Glenmark Pharmaceuticals is currently trading at Rs. 1941.90, up by 20.95 points or 1.09% from its previous closing of Rs. 1920.95 on the BSE.
The scrip opened at Rs. 1934.95 and has touched a high and low of Rs. 1958.00 and Rs. 1925.00 respectively. So far 32058 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 1958.00 and Rs. 1825.00 respectively. The current market cap of the company is Rs. 54645.36 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.38% and 13.97% respectively.
Glenmark Pharmaceuticals has received Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status from the United States Food & Drug Administration (USFDA) for its formulations manufacturing facility situated in Monroe, North Carolina, USA. This is following an inspection conducted by the Agency from June 09 to June 17 2025. The commercial manufacturing at the Monroe site will now restart.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
